AP1S2

Across TCGA pan-cancer cohorts, AP1S2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of AP1S2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where AP1S2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types AP1S2 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, LUAD, and LUSC are the cancer types where AP1S2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AP1S2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.859	<.001	11	view →
LUAD	Female	III,IV	−1.328	<.001	8	view →
LUSC	All	II,III,IV	−1.043	<.001	8	view →
BLCA	Male	IV	−1.389	.003	5	view →
LIHC	All	II,III,IV	+0.752	.001	4	view →
COAD	All	All	−0.373	.025	4	view →
CHOL	All	All	+1.320	<.001	3	view →
READ	Female	All	−1.389	.031	2	view →
UCEC	All	II,III,IV	+1.158	.041	2	view →
PRAD	All	All	−0.395	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

AP1S2–KIRC

Open the KIRC breakdown →